The nonparametric two-stage Bayesian adaptive design is a novel phase II clinical trial design for finding the minimum effective dose (MinED). This design is motivated by the top priority and concern of clinicians when testing a new drug, which is to effectively treat patients and minimize the chance of exposing them to subtherapeutic or overly toxic doses. It is used to design single-agent trials.
|Author||Chia-Wei Hsu, Fang Wang, Rongji Mu, Haitao Pan, Guoying Xu|
|Maintainer||Chia-Wei Hsu <Chia-Wei.Hsu@stjude.org>|
|Package repository||View on CRAN|
Install the latest version of this package by entering the following in R:
Any scripts or data that you put into this service are public.
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.